PAVmed Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$2.62next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
EsoGuard Test Volume Quarterly3.2K
EsoGuard Quarterly Revenue Quarterly1.3M
Scope 1 Greenhouse Gas Emissions Annually65.4
Scope 2 Greenhouse Gas Emissions Annually50.4
Watch Items
- Medicare Local Coverage Determination (LCD) for EsoGuardTrigger: Publication of positive draft or final LCDAction: Triggers callability of up to $30 million in additional Series D Preferred Stock warrants to fund commercial expansion.
- FDA Submission of Veris Implantable Physiological MonitorTrigger: Submission by end of 2026Action: Monitor regulatory progress and battery life optimization milestones (targeting 2-year battery life).
- Cash Runway and Capital RaisesTrigger: Cash balance falling below $5 millionAction: Evaluate additional asset acquisitions or commercial expansion beyond Ohio State University (OSU) aligned with capital availability.
Research as of 20 Jun 2026